With regard to the safety of A. sativum, the use of this drug in animals for the inhibition of myointimal hyperplasia was successful, without any difference in the presence of steatosis, cholangitis, and portal infiltration between groups. A. sativum has a LD50 of 3034 mg.kg-1 and maximum dosage without side effects of 2200 mg.kg-1; moreover, it is not contraindicated in pregnant animals.